GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mercury Biopharmaceutical Corp (ROCO:6932) » Definitions » Total Assets

Mercury Biopharmaceutical (ROCO:6932) Total Assets : NT$353.20 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mercury Biopharmaceutical Total Assets?

Mercury Biopharmaceutical's Total Assets for the quarter that ended in Dec. 2024 was NT$353.20 Mil.

During the past 12 months, Mercury Biopharmaceutical's average Total Assets Growth Rate was 12.30% per year. During the past 3 years, the average Total Assets Growth Rate was 124.50% per year. During the past 5 years, the average Total Assets Growth Rate was 922.20% per year.

During the past 6 years, Mercury Biopharmaceutical's highest 3-Year average Total Assets Growth Rate was 2715.70%. The lowest was 124.50%. And the median was 2047.90%.

Total Assets is connected with ROA %. Mercury Biopharmaceutical's annualized ROA % for the quarter that ended in Dec. 2024 was -17.63%. Total Assets is also linked to Revenue through Asset Turnover. Mercury Biopharmaceutical's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.

Mercury Biopharmaceutical Total Assets Historical Data

The historical data trend for Mercury Biopharmaceutical's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mercury Biopharmaceutical Total Assets Chart

Mercury Biopharmaceutical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial 0.10 13.38 229.93 438.08 353.20

Mercury Biopharmaceutical Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 229.93 459.20 438.08 378.81 353.20

Mercury Biopharmaceutical Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Mercury Biopharmaceutical's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=290.274+62.929
=353.20

Mercury Biopharmaceutical's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (Q: Dec. 2024 )+Total Liabilities (Q: Dec. 2024 )
=290.274+62.929
=353.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mercury Biopharmaceutical  (ROCO:6932) Total Assets Explanation

Total Assets is connected with ROA %.

Mercury Biopharmaceutical's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=-64.532/( (378.809+353.203)/ 2 )
=-64.532/366.006
=-17.63 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Mercury Biopharmaceutical's Asset Turnover for the quarter that ended in Dec. 2024 is

Asset Turnover
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0.246/( (378.809+353.203)/ 2 )
=0.246/366.006
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Mercury Biopharmaceutical Total Assets Related Terms

Thank you for viewing the detailed overview of Mercury Biopharmaceutical's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Mercury Biopharmaceutical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mercury Biopharmaceutical Corp (ROCO:6932) » Definitions » Total Assets
Comparable Companies
ROCO:4166 ROCO:1799 TPE:4746 ROCO:4120 ROCO:6785 ROCO:4747 TPE:1731 TPE:4119 TPE:4108 ROCO:4132 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
N/A
Address
No. 653-1, Bannan Road, 15th Floor, Zhonghe District, New Taipei City, TWN
Website
https://www.merdury.com.tw
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.

Mercury Biopharmaceutical Headlines

No Headlines